Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.643
+0.023 (+1.45%)
Streaming Delayed Price
Updated: 11:41 AM EDT, Mar 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
Next >
OKYO Pharma Announces Chairman and Founder Acquires Shares
March 19, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Director Acquires Shares
March 19, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
March 19, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
March 18, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
February 23, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
February 12, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Public Offering of Ordinary Shares
February 12, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
February 11, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
February 10, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
January 30, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 28, 2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach
From
OKYO Pharma LTD
Via
GlobeNewswire
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
January 23, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
January 05, 2026
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Ring the Opening Bell at Nasdaq
December 19, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
December 15, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
December 11, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
December 03, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
November 21, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at OIS XV in San Diego
November 18, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
October 29, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
October 16, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
September 22, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
July 17, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
July 16, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
June 11, 2025
Via
ACCESS Newswire
OKYO Pharma to Present at the Bio International Convention
June 11, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
May 19, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
May 01, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
April 30, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
March 31, 2025
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
